Pawel Sobczuk, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, previews the upcoming ESMO Congress 2023 in Madrid, Spain.
Pawel Sobczuk, MD, PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland, and European Society of Medical Oncology (ESMO) Young Oncologists Committee member, previews the upcoming ESMO Congress 2023 in Madrid, Spain.
This transcript has been lightly edited for clarity.
Transcript
What can we look forward to at ESMO 2023?
The majority of participants on social media are saying it's the biggest congress and the most interesting one. There’ll be plenty of new data presented during the congress, including results of recent phase 3 studies in different tumor types, some of them included in the presidential symposia. This will include some studies into lung cancer, gynecological cancers, or in breast cancer, so there is plenty of new data coming during this year’s ESMO. And besides that, we'll have multiple presentations from a broad spectrum, including basic science, phase 1/phase 2 trials, and retrospective data. Everyone can find something for themselves.
Are there any sessions you would like to highlight?
Besides the scientific sessions where new data will be presented, there are multiple educational sessions, including keynote lectures. Some of them are very important in the current times, such as new cancer hallmarks for 2023, or how to manage oncological care in times of crisis.
ESMO is also putting a lot of effort into sustainability of health care. We’ll have a dedicated session organized by a climate change task force that will deal with the issue of how to make oncology care more sustainable and how to implement the issues related to climate change. This is the session that shouldn't be missed by participants who will be joining us in Madrid, because this is the session that will not be livestreamed. This will only be for participants on site. There will be also sessions about the resilience of the health care professionals. These might be the most valuable for anyone, irrespective of the tumor type oncologists are dealing with.
What are some of the goals of ESMO this year?
ESMO this year will also present the first guidelines for reporting real-world evidence. This a big step forward that moves us a bit from clinical trials to real-world data that are gaining much more importance in recent years for common tumors—but these are also very important for rare cancers. This is a big step forward that shows not only new phase 3 data—that we will have plenty of during these year's ESMO—but also how real-world evidence is crucial in the current landscape of oncology science.
Real-World Data Show Sotorasib Effective for NSCLC With KRAS Mutation
May 18th 2024Data from real-world and clinical-trial settings on frontline monotherapy treatment with the KRAS inhibitor sotorasib both show similar progression-free survivals and a high likelihood that the treatment’s efficacy is not affected with dose reduction.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More